다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Cancer research and treatment : official journal of Korean Cancer Association, v.49 no.1, 2017년, pp.246 - 254
Jung, Hae Il (Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea) , Jeong, Dongjun (Soonchunhyang Medical Science Research Institute, Soonchunhyang University College of Medicine, Cheonan, Korea) , Ji, Sanghee (Soonchunhyang Medical Science Research Institute, Soonchunhyang University College of Medicine, Cheonan, Korea) , Ahn, Tae Sung (Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea) , Bae, Sang Ho (Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea) , Chin, Susie (Department of Pathology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea) , Chung, Jun Chul (Department of Surgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea) , Kim, Hyung Chul (Department of Surgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea) , Lee, Moon Soo (Department of Surgery, Soonchunhyang University Cheonan Hospital,) , Baek, Moo-Jun
AI-Helper
PurposeHepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Recently, the overexpression of programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) has been shown to correlate with poor prognosis in many cancers. However, the expression of PD-L1 or PD-1 ligand 2 (PD-L2) and cl...
1 El-Serag HB Hepatocellular carcinoma N Engl J Med 2011 365 1118 27 21992124
2 Vilarinho S Taddei T Therapeutic strategies for hepatocellular carcinoma: new advances and challenges Curr Treat Options Gastroenterol 2015 13 219 34 25791207
3 Sangro B Palmer D Melero I Immunotherapy of hepatocellular carcinoma Hepat Oncol 2014 1 433 46
4 Ohaegbulam KC Assal A Lazar-Molnar E Yao Y Zang X Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway Trends Mol Med 2015 21 24 33 25440090
5 Ma H Wey B Li L Progress of immunotherapy for hepatocellular carcinoma Immunogastroenterology 2013 2 167 72
6 Qing Y Li Q Ren T Xia W Peng Y Liu GL Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer Drug Des Devel Ther 2015 9 901 9
7 Pan ZK Ye F Wu X An HX Wu JX Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis J Thorac Dis 2015 7 462 70 25922726
8 Tentori L Lacal PM Graziani G Challenging resistance mechanisms to therapies for metastatic melanoma Trends Pharmacol Sci 2013 34 656 66 24210882
9 Thompson RH Dong H Lohse CM Leibovich BC Blute ML Cheville JC PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin Cancer Res 2007 13 1757 61 17363529
10 Nomi T Sho M Akahori T Hamada K Kubo A Kanehiro H Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin Cancer Res 2007 13 2151 7 17404099
11 Hamanishi J Mandai M Iwasaki M Okazaki T Tanaka Y Yamaguchi K Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 2007 104 3360 5 17360651
12 McDermott DF Atkins MB PD-1 as a potential target in cancer therapy Cancer Med 2013 2 662 73 24403232
13 Gao Q Wang XY Qiu SJ Yamato I Sho M Nakajima Y Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 2009 15 971 9 19188168
14 Wang BJ Bao JJ Wang JZ Wang Y Jiang M Xing MY Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma World J Gastroenterol 2011 17 3322 9 21876620
15 Zeng Z Shi F Zhou L Zhang MN Chen Y Chang XJ Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma PLoS One 2011 6 e23621 21912640
16 He L Zhang G He Y Zhu H Zhang H Feng Z Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma Anticancer Res 2005 25 3309 13 16101143
17 Rozali EN Hato SV Robinson BW Lake RA Lesterhuis WJ Programmed death ligand 2 in cancer-induced immune suppression Clin Dev Immunol 2012 2012 656340 22611421
18 Huber S Hoffmann R Muskens F Voehringer D Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2 Blood 2010 116 3311 20 20625006
19 Hamid O Robert C Daud A Hodi FS Hwu WJ Kefford R Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 2013 369 134 44 23724846
20 Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 2443 54 22658127
21 Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 64 22437870
22 Tiegs G Lohse AW Immune tolerance: what is unique about the l iver J Autoimmun 2010 34 1 6 19717280
23 Sangro B Gomez-Martin C de la Mata M Inarrairaegui M Garralda E Barrera P A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C J Hepatol 2013 59 81 8 23466307
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.